Kidney transplantation: Current issues and future prospects

Acta Clinica Belgica

Volumn 62, Issue 4, 2007, Pages 208-217

  Kuypers, Dirk R J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Allocation; Complications; Donation; Graft monitoring; Immunosuppressive drugs; Outcome; Pharmacogenetics; Protocol biopsies; Renal transplantation

Indexed keywords

ANTIBIOTIC AGENT; ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; GLUCOCORTICOID; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VORICONAZOLE;

ABDOMINAL PAIN; BACTERIAL INFECTION; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIARRHEA; DRUG WITHDRAWAL; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KAPOSI SARCOMA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; ORGAN DONOR; REVIEW; SKIN CANCER;

EID: 34547777399     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2007.034     Document Type: Review

References (86)

1. National Institute of Health NIDDK/DKUHD. United States Renal Data System. USRDS 2006 Annual Data Report. Am J Kidney Dis. 2007; 49 (Suppl 1): S1-S296.
2. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004; 4(8): 1289-95.
3. Das KK, Lerner BH. Opportunities not taken: Successes and shortcomings in the Institute of Medicine's report on organ donation. Kidney Int. 2007; 71(8): 726-9.
4. Tantravahi J, Womer KL, Kaplan B. Why hasn't eliminating acute rejection improved graft survival? Annu Rev Med. 2007; 58: 369-85.
5. Studer SM, Orens JB. Cadaveric donor selection and management. Semin Respir Crit Care Med. 2006; 27(5): 492-500.
6. Lopez-Navidad A, Caballero F. Extended criteria for organ acceptance. Strategies for achieving organ safety and for increasing organ pool. Clin Transplant. 2003; 17(4): 308-24.
7. Moers C, Leuvenink HG, Ploeg RJ. Non-heart beating organ donation: overview and future perspectives. Transpl Int. 2007 Jan 29.
8. Squifflet JP. Why did it take so long to start a non-heart-beating donor programme in Belgium? Acta Chir Belg. 2006; 106(5): 485-8.
9. Keizer KM, de Fijter JW, Haase-Kromwijk BJ, Weimar W. Non-heart-beating donor kidneys in the Netherlands: allocation and outcome of transplantation. Transplantation. 2005; 79(9): 1195-9.
10. .Snoeijs MG, Wiermans B, Christiaans MH et al. Recipient hemodynamics during non-heart-beating donor kidney transplantation are major predictors of primary nonfunction. Am J Transplant. 2007 Feb 27.
11. Delmonico FL. What is the system failure? Kidney Int. 2006; 69(6): 954-5.
12. Haddow G. "Because you're worth it?" The taking and selling of transplantable organs. J Med Ethics. 2006; 32(6): 324-8.
13. Appel JM. Wanted dead or alive? Kidney transplantation in inmates awaiting execution. J Clin Ethics. 2005; 16(1): 58-60.
14. de Klerk M, Keizer KM, Claas FH, Witvliet M, Haase-Kromwijk BJ, Weimar. The Dutch national living donor kidney exchange program. Am J Transplant. 2005; 5(9): 2302-5.
15. de Klerk M, Witvliet MD, Haase-Kromwijk BJ, Claas FH, Weimar W. A highly efficient living donor kidney exchange program for both blood type and crossmatch incompatible donor-recipient combinations. Transplantation. 2006; 82(12): 1616-20.
16. Steinberg D. The allocation of organs donated by altruistic strangers. Ann Intern Med. 2006; 145(3): 197-203.
17. Kokkinos C, Nanidis T, Antcliffe D, Darzi AW, Tekkis P, Papalois V. Comparison of laparoscopic versus hand-assisted live donor nephrectomy. Transplantation. 2007; 83(1): 41-7.
18. Prasad GV, Garg AX. Need for a registry of living kidney donor outcomes. Transplantation. 2006; 82(10): 1383.
19. Fehrman-Ekholm I, Norden G, Lennerling A et al. Incidence of end-stage renal disease among live kidney donors. Transplantation. 2006; 82(12): 1646-8.
20. Clemens KK, Thiessen-Philbrook H, Parikh CR et al. Psychosocial health of living kidney donors: a systematic review. Am J Transplant. 2006; 6(12): 2965-77.
21. Fabrizii V, Kovaric J, Bodingbauer M, Kramar R, Horl WH, Winkelmayer WC. Long-term patient and graft survival in the eurotransplant senior program: a single-center experience. Transplantation. 2005; 80(5): 582-9.
22. Giessing M, Budde K, Fritsche L et al. "Old-for-old" cadaveric renal transplantation: surgical findings, perioperative complications and outcome. Eur Urol. 2003; 44(6): 701-8.
23. Cohen B, Smits JM, Haase B, Persijn G, Vanrenterghem Y, Frei U. Expanding the donor pool to increase renal transplantation. Nephrol Dial Transplant. 2005; 20(1): 34-41.
24. Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. Curr Drug Metab. 2002; 3(3): 275-87.
25. Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther. 2006; 112(1): 184-98.
26. Gaston RS. Current and evolving immunosuppressive regimens in kidney transplantation. Am J Kidney Dis. 2006; 47(4 Suppl 2): S3-21.
27. Samaniego M, Becker BN, Djamali A. Drug insight: maintenance immunosuppression in kidney transplant recipients. Nat Clin Pract Nephrol. 2006; 2(12): 688-99.
28. Matas AJ, Kandaswamy R. The current role of calcineurin inhibitors in posttransplant immunosuppression? Am J Transplant. 2006; 6(12): 2827-9.
29. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349(24): 2326-33.
30. Abramowicz D, Del Carmen Rial M, Vitko S et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol. 2005; 16(7): 2234-40.
31. Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant. 2004; 4(11): 1776-85.
32. Ekberg H, Grinyo J, Nashan B et al. Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study. Am J Transplant. 2007; 7(3): 560-70.
33. Gelens MA, Christiaans MH, van Heurn EL, van den Berg-Loonen EP, Peutz-Kootstra CJ, van Hooff JP. High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation. Transplantation. 2006; 82(9): 1221-3.
34. Kuypers D, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant. 2003; 17(3): 234-41.
35. Srinivas TR, Schold JD, Guerra G, Eagan A, Bucci CM, Meier-Kriesche HU. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant. 2007; 7(3): 586-94.
36. Srinivas TR, Kaplan B, Schold JD, Meier-Kriesche HU. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation. 2005; 80(2 Suppl): S211-20.
37. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998; 34(6): 429-55.
38. Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation. 2006; 82(11): 1413-8.
39. Meier-Kriesche HU. Mycophenolate mofetil-based immunosuppressive minimization and withdrawal strategies in renal transplantation: possible risks and benefits. Curr Opin Nephrol Hypertens. 2006; 15 Suppl 1: S1-5.
40. Kuypers D, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther. 2004; 75(5): 434-47.
41. Naito T, Shinno K, Maeda T et al. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol Pharm Bull. 2006; 29(2): 275-80.
42. Appel GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation. 2005; 80(2 Suppl): S265-71.
43. Cole E, Landsberg D, Russell D et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation. 2001; 72(5): 845-50.
44. Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation. 2005; 79(7): 807-14.
45. Vanrenterghem Y, van Hooff JP, Squifflet JP et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant. 2005; 5(1): 87-95.
46. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation. 2000; 70(9): 1352-9.
47. Abramowicz D, Vanrenterghem Y, Squifflet JP et al. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial. Clin Transplant. 2005; 19(4): 475-82.
48. Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother. 2001; 2(11): 1903-17.
49. Trepanier DJ, Gallant H, Legatt DF, Yatscoff RW. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem. 1998; 31(5): 345-51.
50. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf. 2005; 28(2): 153-81.
51. Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol. 2004; 15(3): 809-17.
52. Hardinger KL. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy. 2006; 26(12): 1771-83.
53. Webster A, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database Syst Rev. 2006; 19(2):CD004756. Review.
54. Ramirez CB, Marino IR. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther. 2007; 7(1): 137-48.
55. Wiland AM, Philosophe B. Daclizumab induction in solid organ transplantation. Expert Opin Biol Ther. 2004; 4(5): 729-40.
56. Evenepoel P, Vanrenterghem Y. Death with functioning graft - a preventable cause of graft loss. Ann Transplant. 2001; 6(4): 17-20.
57. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000; 57(1): 307-13.
58. Silkensen JR. Long-term complications in renal transplantation. J Am Soc Nephrol. 2000; 11(3): 582-8.
59. Parasuraman R, Yee J, Karthikeyan V, del Busto R. Infectious complications in renal transplant recipients. Adv Chronic Kidney Dis. 2006; 13(3): 280-94.
60. Hanson K, Alexander B. Strategies for the prevention of infection after solid organ transplantation. Expert Rev And Infect Ther. 2006; 4(5): 837-52.
61. Marty FM, Rubin RH. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. Transpl Int. 2006; 19(1): 2-11.
62. The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System. USRDS 1999 Annual Data Report. Am J Kidney Dis. 1999, 34 (Suppl 1): S1-S176.
63. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006; 82(5): 603-11.
64. Rigatto C, Parfrey P. Therapy insight: management of cardiovascular disease in the renal transplant recipient. Nat Clin Pract Nephrol. 2006; 2(9): 514-26.
65. Morales JM, Dominguez-Gil B. Impact of tacrolimus and mycophenolate mofetil combination on cardiovascular risk profile after kidney transplantation. J Am Soc Nephrol. 2006; 17(12 Suppl 3): S296-303.
66. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003; 361(9374): 2024-31.
67. Holdaas H, Fellstrom B, Cole E et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005; 5(12): 2929-36.
68. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther. 2000; 7(2): 147-56.
69. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000; 23(2): 101-13.
70. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C et al. Cancer after kidney transplantation in the United States. Am J Transplant. 2004; 4(6): 905-13.
71. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA. 2006; 296(23): 2823-31.
72. Svoboda J, Kotloff R, Tsai DE et al. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int. 2006; 19(4): 259-69.
73. Chapman JR, O'Connell PJ, Nankivell BJ et al. Chronic renal allograft dysfunction. J Am Soc Nephrol. 2005; 16(10): 3015-26.
74. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation. 2006; 81(5): 643-54.
75. Hariharan S. BK virus nephritis after renal transplantation. Kidney Int. 2006; 69(4): 655-62.
76. Lampen A, Christians U, Guengerich FP et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos. 1995; 23: 1315-24.
77. Kamdem LK Streit F, Zanger UM et al. Contribution of CYP3A5 to the in vitro hepatic clearence of Tacrolimus. Clin Chemistry. 2005; 51: 1374-81.
78. Anglicheau D, Verstuyft C, Laurent-Puig P et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003; 14(7): 1889-96.
79. Kuypers DR, Naessens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther. 2005; 78(4): 351-61.
80. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006; 82(8): 1074-84.
81. Isoniemi HM, Krogerus L, von Willebrand E, Taskinen E, Ahonen J, Häyry P. Histopathological findings in well-functioning, long-term renal allografts. Kidney Int. 1992; 41: 155-160.
82. Nickerson P, Jeffery J, Gough J, et al. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection, a pilot study. J Am Soc Nephrol. 1999; 10: 1801-5.
83. Nankivell B, Borrows R, Fung C, O'Connell Ph, Allen R, Chapman J. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation. 2004; 78: 242-249.
84. Nankivell B, Fenton-Lee C, Kuypers D, et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation. 2001; 71: 515-23.
85. Mansfield E, Sarwal M. Arraying the orchestration of allograft pathology. Am J Transplant. 2004; 4: 853-862.
86. Wittke S, Haubitz M, Walden M et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant. 2005; 5: 2479-88.